Fat Burners

Clenbuterol 0,04 mg Hilma Biocare

Hilma Biocare

40,00

In Stock (100 available)

Clenbuterol 0,04 mg Hilma Biocare (0,04 mg) — The thermogenic effects of Clenbuterol — a 10–15% increase in basal metabolic rate — have established it as the cornerstone …

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost
Categories: ,

Description

Clenbuterol 0,04 mg Hilma Biocare — clenbuterol from Hilma Biocare at 0.04 mg. Long-half-life beta-2 agonist (36–48 h) — dose accumulates over several days. Titrate slowly. Cycle 2-on/2-off to preserve receptor sensitivity.

Key Benefits

  • Beta-2 agonist — raises basal metabolic rate and lipolysis
  • 2-on / 2-off protocol to prevent beta-receptor downregulation
  • Titrate slowly — tremors and tachycardia above 80 mcg/day
  • Supplement taurine 3–5 g/day and potassium
  • Supporting compound — diet deficit does 90% of the work
  • Each unit dosed at 04 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: start 20 mcg/day, titrate by 20 mcg every 2–3 days to 80–120 mcg/day. Two-week on / two-week off cycling prevents beta-2 receptor downregulation. Split dose AM + midday — avoid late-day dosing (insomnia).

How It Works

Selective beta-2 adrenergic agonist. Raises basal metabolic rate, promotes lipolysis, mildly anti-catabolic. Increases body temperature and heart rate. Tissue specificity favours fat over muscle at therapeutic doses.

Pharmacokinetics

Plasma half-life approximately 26–36 hours. Daily dosing. Steady-state in 4–5 days. Receptor downregulation develops after 2 weeks of continuous use — hence cycling.

Potential Side Effects

Tremors, tachycardia, cramps (taurine deficit), insomnia, sweating. Tachycardia persistent above 100 bpm — drop dose. Cardiac hypertrophy risk on long runs. Not for cardiovascular-compromised users.

Cycle & Stacking Guide

2-on / 2-off cycling typical, up to 6–8 weeks total within a cutting phase. Stacks with T3 (aggressive) or with fat-loss AAS protocol (test + var + clen). Always with taurine 3–5 g/day and potassium/magnesium supplementation.

Manufacturer Notes

Hilma Biocare operates a Romanian GMP site with dedicated HPLC bays. Their catalogue emphasises clean oil carriers (often MCT or ethyl oleate) to reduce post-injection pain.

Storage & Handling

Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Clenbuterol 0,04 mg Hilma Biocare”

Your email address will not be published. Required fields are marked *

Clenbuterol

Physical & Chemical Properties for Research Purposes
Chemical structure of Clenbuterol (C12H18Cl2N2O) for laboratory analysis
2D structural representation · PubChem CID 2783 ↗
Chemical Identity
# CAS Registry Number 37148-27-9
Σ IUPAC Name 1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol
F Molecular Formula C12H18Cl2N2O
M Molecular Weight 277.19 g/mol
SMILES CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1
InChIKey OPXKTCUYRHXSBK-UHFFFAOYSA-N
Melting Point 174-175 °C
Solubility Soluble in water, ethanol, methanol
Biological Half-life 36-48 hours (oral)
PubChem CID 2783 ↗
Pharmacological Profile
Aromatization None
Hepatotoxicity None
Known trade names: Spiropent, Ventipulmin, Clenbuterol Sopharma

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.